| Previous Close | 4,141.81 |
| Open | 4,165.71 |
| Volume | 0 |
| Day's Range | 4,142.12 - 4,213.58 |
| 52 Week Range | 2,947.85 - 4,273.52 |
| Avg. Volume | 325,953 |
SOUTH SAN FRANCISCO, Calif., Dec. 20, 2019 -- Alector Inc. (Nasdaq: ALEC), a clinical stage biotechnology company pioneering immuno-neurology, today announced that it has been.
Scholar Rock Holding Corporation (SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq:NBI), effective prior to market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed to track the performance of a set of NASDAQ-listed securities that are classified as either Biotechnology or Pharmaceutical according to the Industry Classification Benchmark (ICB). The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (IBB).
RALEIGH, N.C., Dec. 19, 2019 -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to.
Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, has been selected for addition to the NASDAQ Biotechnology Index® (^NBI), as part of the annual index evaluation. The Company’s addition to the index will become effective prior to the market open on Monday, December 23, 2019. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
NEW YORK, Dec. 13, 2019 -- Nasdaq (Nasdaq:NDAQ) today announced the results of the annual evaluation of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective.